Vericel Corporation (NASDAQ:VCEL) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
As disclosed in the Original Report, on May9, 2017, the Company
entered into the Loan Modification Agreement. The description of
the Loan Modification Agreement included in the Original Report
is hereby incorporated by reference into this Form8-K/A. The Loan
Modification Agreement is attached to this Form8-K/A as
Exhibit10.1.
Item 2.02 Results of Operations and Financial
Condition.
The information set forth in Item 2.02 of the Original Report is
incorporated by reference as if fully set forth herein.
Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant.
The information set forth in Item 2.03 of the Original Report is
incorporated by reference as if fully set forth herein.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d)Exhibits.
|
ExhibitNo. |
|
Description |
|
10.1 * |
Second Loan Modification Agreement dated May9, 2017 between |
|
|
99.1 |
Press Release of Vericel Corporation, Vericel Reports |
* Confidential treatment has been requested as to certain
portions thereto, which portions are omitted and will be filed
separately with the Securities and Exchange Commission.
Filed herewith.
Previously filed.
About Vericel Corporation (NASDAQ:VCEL)
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy. Vericel Corporation (NASDAQ:VCEL) Recent Trading Information
Vericel Corporation (NASDAQ:VCEL) closed its last trading session up +0.03 at 3.03 with 424,176 shares trading hands.
